Agenus Inc. Investors: Important Deadline Approaching for Class Action
As an investor in Agenus Inc. (NASDAQ: AGEN), staying informed about significant legal developments is crucial. Bernstein Liebhard LLP, a prominent law firm specializing in investor rights, is urging Agenus shareholders to take note of an upcoming deadline related to a critical class action lawsuit.
Understanding the Class Action Lawsuit
Many investors may wonder what this lawsuit entails. Essentially, it revolves around allegations of securities fraud during a specific time frame. If you purchased shares of Agenus between January 23, 2023, and July 17, 2024, you could be impacted by these claims. The lawsuit alleges that the company made various misrepresentations regarding the advancement of its investigational therapy aimed at treating metastatic colorectal cancer patients.
Key Questions for Investors
Here are a few essential questions all current and former shareholders should consider:
Do you own shares in Agenus?
If you have made investments in Agenus, especially within the identified time frame, you may need to explore your legal rights further.
Have you experienced financial losses?
In light of potential misrepresentations by the company, it is vital to assess your investment's performance and any losses you may have incurred.
Are you interested in discussing your options?
If you have concerns about your investment, consulting with legal experts could provide clarity on your situation and potential next steps.
What to Do Next
For those wishing to participate as lead plaintiffs in this class action, it is essential to file the necessary paperwork by November 5, 2024. Being a lead plaintiff means taking on the role of representing other investors in the lawsuit. However, it's important to understand that you can still benefit from any recovery even if you choose not to take this role.
Contingency Fee Basis
One reassuring aspect of this legal action is that all legal representation is offered on a contingency fee basis. This means that shareholders will incur no out-of-pocket costs for legal fees unless the case is won, making it a low-risk option for pursuing justice.
Why Choose Bernstein Liebhard LLP?
With a reputation for excellence in litigation, Bernstein Liebhard LLP has successfully recovered over $3.5 billion for its clients since its inception in 1993. The firm has gained significant recognition and has been retained by some large public and private pension funds to protect their investments. Their extensive experience in handling similar class actions demonstrates their capability in advocating for shareholders' rights.
Contact Information for Further Inquiries
If you wish to learn more about your potential involvement in the class action or discuss your rights as an investor in Agenus, reach out to Investor Relations Manager, Peter Allocco, at (212) 951-2030. For additional information, you may also contact him via email.
Frequently Asked Questions
What is the deadline for filing papers to be a lead plaintiff?
The deadline to file papers to serve as lead plaintiff is November 5, 2024.
What should I do if I own Agenus shares?
If you own shares, consider reviewing your investment with a legal professional to explore your rights and potential claims.
Can I still participate if I don't want to be a lead plaintiff?
Yes, you can still benefit from any recovery without taking on the lead plaintiff role.
Is there a fee to join the class action?
No, there are no fees or expenses unless the case is won, as representation is on a contingency fee basis.
Who can I contact for more information?
You can contact Peter Allocco, the Investor Relations Manager at Bernstein Liebhard LLP, for further inquiries regarding the lawsuit.
